Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHRONULAC vs CLENPIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
Cleansing of the colon as a preparation for colonoscopy in adults
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
Negligible (<5%), primarily to albumin.
Sodium picosulfate: <5% bound to plasma proteins
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration)
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-59 m L/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only).
No adjustment needed; used in hepatic encephalopathy at higher doses.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B).
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
No specific dose adjustment required solely based on age. Consider renal function (e GFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment).
None.
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Risk of fluid and electrolyte abnormalities,Cardiac arrhythmias due to electrolyte imbalance,Seizures associated with electrolyte abnormalities,Renal impairment,Mucosal ulceration,Use with caution in patients with impaired gag reflex, reflux, or aspiration risk,Colonic mucosal aphthous ulcerations
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Hypersensitivity to any component,Severe renal impairment (e GFR <30 m L/min/1.73m²)
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
Avoid solid food during bowel preparation. Only clear liquids (water, clear broth, black coffee/tea, clear fruit juices without pulp, gelatin, popsicles) are permitted. Do not consume milk, cream, or any dairy products. Avoid red or purple colored liquids that may be mistaken for blood during colonoscopy. Do not consume alcohol.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
No dose adjustment recommendations available due to lack of pharmacokinetic studies in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal blood flow) may affect drug disposition; use lowest effective dose and ensure adequate hydration. No specific dose reduction recommended.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
CLENPIQ (sodium picosulfate, magnesium oxide, and citric acid) is a colonoscopy preparation. Ensure adequate hydration before, during, and after use. Common adverse effects include nausea, vomiting, and abdominal distension. Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min), gastrointestinal obstruction, ileus, or known hypersensitivity. Avoid use within 1 hour of antacids or medications that affect gastrointestinal motility.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
Take CLENPIQ as a split-dose regimen: one bottle the evening before and one bottle the morning of the colonoscopy.,Do not take any other laxatives or bowel preparations concurrently.,Stay hydrated by drinking clear liquids before and after each dose.,Do not eat solid food during the preparation period; only clear liquids are allowed.,Common side effects include nausea, bloating, and abdominal cramps; contact your doctor if severe or persistent.,Avoid driving or operating machinery if you feel dizzy or lightheaded.,Inform your doctor of all medications, especially diuretics, ACE inhibitors, ARBs, NSAIDs, or any drugs affecting kidney function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHRONULAC vs CLENPIQ, answered by our medical review team.
CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. CLENPIQ is a Laxative that works by Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHRONULAC and CLENPIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. The standard adult dose of CLENPIQ is: Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHRONULAC and CLENPIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . CLENPIQ is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.